CEO Today Management Consulting Awards 2021

UNITED KINGDOM

CEO TODAY MANAGEMENT CONSULTING AWARDS 2021

JON

Contact Details E: contact@pharmalex.com W: www.pharmalex.com

JEFFERY Head UK / Ireland Region and Managing Director PharmaLex UK

ABOUT JON JEFFERY After joining the company that became PharmaLex UK, Jon was appointed as Managing Director shortly before he reached the age of 40. He has since led the businessʼs strong organic and inorganic growth, achieving or exceeding the P&L targets year-on-year. On 1 January 2020, PharmaLex UK and Ireland joined forces and Jon now leads a regional organization that provides outstanding program-led and thought-leadership solutions to its clients across the PharmaLex service portfolio. Aiming to be inspirational and accessible to all parts of the organization, Jonʼs colleagues know him for being both strategic and tactical with sight on the big picture as well as the detail. During his career, Jon has supported organizations as a regulatory consultant and his clients have appreciated his commercial outlook having worked in both sales and marketing roles. With over 25 years of life sciences industry experience working for European and North American companies and clients of all sizes, Jon has covered prescription and OTC medicines, original and generic, and has provided support for registrations with an array of global regulatory authorities, across Europe, North America, the Middle East and APAC. FIRMPROFILE PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. Founded in 1994, PharmaLex has 40 offices in 22 countries and continues to see healthy growth. Our purpose is to support the life sciences industry to transform global health by accelerating the development of life-changing products for patients. Differentiation PharmaLex delivers compliance solutions for pharma, biotech and medtech companies who require expert knowledge or resources. Scalable yet innovative, our high-quality, specialized services go beyond market approval to maintain product portfolios. We have a vast network of trusted global consultants who help clients navigate local regulations. Our diversity provides a distinct advantage in an era when flexibility

and efficiency are key to competitiveness. We draw from the combined knowledge of the whole spectrum of life sciences with 25+ years of experience. Compared to some of the large CROs / BPO organizations, PharmaLex is considered a specialist business organization. What CROs consider a side business, is our core business. Leading technological innovation At PharmaLex we combine our extensive global experience and deep understanding of pharmaceutical lifecycle processes with the development of our cloud-based platform for life sciences automation alongside key partnerships with leading technology vendors. Through our pharma technology-enabled services we are helping our customers to adopt and take advantage of innovative technologies to drive efficiency gains within their own operations. Living our values Our values are the backbone of PharmaLex. They guide us in our decision-making and how we engage with our colleagues and clients every day. To make them truly meaningful, we developed them together with our team across our global network and embedded them in our processes to ensure they are lived. Social responsibility As an industry leading company compliance is our priority. But it doesnʼt stop there. Our ethos is to provide flexible and cost-effective solutions that enable companies to bring products intended to diagnose, treat and improve patient wellbeing tomarket faster. It is this commitment coupled with the acknowledgement of the impact our business model has on the world, that defines our corporate social responsibility strategy. It is of vital importance that we not only take responsibility for our actions as a company but invest in our future as a community. Our values are international mindset, growth and learning, collaboration, quality focus, dynamic working approach and integrity and respect.

35